Evidence map›Paper›PMID 19498436›Full record

ReviewNature reviews. Neurology2009

Hallucinations in Parkinson disease.

Nico J Diederich, Gilles Fénelon, Glenn Stebbins, Christopher G Goetz

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Neurology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 124 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04579887 naunknown statusnot on this mapstarted 2020, after this paper: background citation

Unravelling Dysfunctional Brain Networks in Patients With Parkinson's Disease Suffering From Presence Hallucination

TypeinterventionalSponsorOlaf BlankeRan2020 to 2021Enrolled10ConditionsParkinson Disease PsychosisArmsBrain changes triggered by PH induction in Parkinson's disease patients with presence hallucinations
NCT04592965 naunknown statusnot on this mapstarted 2020, after this paper: background citation

Unravelling Dysfunctional Brain Networks in Patients With Parkinson's Disease Suffering From Hallucinations

TypeinterventionalSponsorOlaf BlankeRan2020 to 2021Enrolled40ConditionsParkinson Disease PsychosisArmsClinical and neuropsychological assessments, Induction of PH and associated bodily states, Resting-state fMRI acquisition, Induction of PH and associated bodily states (MRI)
3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. FDG-PET assessment and metabolic patterns in Lafora disease.European journal of nuclear medicine and molecular imaging · 2020
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. The heterogeneity of non-motor symptoms of Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2015
    Trial
  13. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2010
    Trial
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nico J DiederichDepartment of Neurology, Center Hospitalier de Luxembourg, 4 rue Barblé, Luxembourg City, Luxembourg. diederdn@pt.lu
Gilles Fénelon
Glenn Stebbins
Christopher G Goetz

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with Parkinson disease (PD) can experience hallucinations (spontaneous aberrant perceptions) and illusions (misinterpretations of real perceptual stimuli). Of such phenomena, visual hallucinations (VHs) and illusions are the most frequently encountered, although auditory, olfactory and tactile hallucinations can also occur. In cross-sectional studies, VHs occur in approximately one-third of patients, but up to three-quarters of patients might develop VHs during a 20-year period. Hallucinations can have substantial psychosocial effects and, historically, were the main reason for placing patients in nursing homes. Concomitant or overlapping mechanisms are probably active during VHs, and these include the following: central dopaminergic overactivity and an imbalance with cholinergic neurotransmission; dysfunction of the visual pathways, including specific PD-associated retinopathy and functional alterations of the extrastriate visual pathways; alterations of brainstem sleep-wake and dream regulation; and impaired attentional focus. Possible treatments include patient-initiated coping strategies, a reduction of antiparkinson medications, atypical neuroleptics and, potentially, cholinesterase inhibitors. Evidence-based studies, however, only support the use of one atypical neuroleptic, clozapine, and only in patients without dementia. Better phenomenological discrimination, combined with neuroimaging tools, should refine therapeutic options and improve prognosis. The aim of this Review is to present epidemiological, phenomenological, pathophysiological and therapeutic aspects of hallucinations in PD.

Indexed as

AnimalsAntipsychotic AgentsCholinesterase InhibitorsCognition DisordersHallucinationsHumansIllusionsLevodopaMagnetic Resonance ImagingNeurotransmitter AgentsParkinson DiseaseSleep Wake DisordersAntipsychotic AgentsCholinesterase InhibitorsLevodopaNeurotransmitter Agents

Identifiers

PMID19498436

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.